An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
VERDICT
The label
Markup
read at $22.92
Adaptive Biotechnologies Corporation holds its Markup at $22.92.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 20 days
Price
$22.92
Valuation
N/A trailing · -96.71 forward price to earnings
Values screen
PASS· score 70.0
Beta
2.07
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$22.92
N/A P/E · -96.71 fwd
Our fair value
$22.00
4% premium
Analyst target (avg)
$22.00
-4% to current
Target low $20.00Analyst target rangeTarget high $25.00
▲ current $22.92 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$22.92
you are here
Conservative
$20.00
-13%
Analyst avg
$22.00
-4%
Our fair value
$22.00
-4%
Analyst high
$25.00
+9%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the Street see limited upside at this price.
Revenue growth
35.10%
Profit margin
-16.82%
Debt to equity
92.84
Analyst consensus
Strong Buy · 7 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Immune sequencing bets still lose cash at scale
Every new immune test that gets ordered in a hospital lab adds another line of revenue for Adaptive Biotechnologies, yet the company still burns cash on every sale. Revenue is growing at 35 percent, which sounds promising for a commercial-stage diagnostics platform, but forward earnings sit at minus 96.7 times sales and profit margins remain negative 17 percent.
We pass because the numbers do not support ownership at current prices. The stock trades above our fair value with a negative margin of safety, return on equity is minus 24 percent, and no economic moat is visible. Analyst targets cluster around the present quote, offering no cushion against further dilution or slower test adoption.
Risk sits with execution and cash burn in a market that already prices in strong buy ratings. Losses could widen if clinical uptake stalls, and the ethical screen offers no offset for the weak financial profile. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
ADPT trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 30.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (7 analysts) rates it strong buy, with a mean price target of $20. Entered 2026-07-20 · Markdown
JOURNAL
The dated journal · newest first, never edited
2026-07-20Markdown$22.92+30.2%Entry 5
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 30.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (7 analysts) rates it strong buy, with a mean price target of $20.
2026-07-18Markdown$17.60+0.0%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (7 analysts) rates it strong buy, with a mean price target of $20.
2026-07-16Markdown$17.60+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (7 analysts) rates it strong buy, with a mean price target of $20.
2026-07-03Markdown$17.60+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markdown$17.60Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$13.54
+29.0%
·
$1,290
+29.0%
2 months
$12.79
+36.6%
·
$1,366
+36.6%
3 months
$12.45
+40.3%
·
$1,403
+40.3%
6 months
$15.42
+13.3%
·
$1,133
+13.3%
1 year
$10.46
+67.0%
·
$1,670
+67.0%
2 years
$3.49
+400.4%
·
$5,004
+400.4%
3 years
$7.31
+138.9%
·
$2,389
+138.9%
5 years
$38.76
-54.9%
·
$451
-54.9%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever ADPT does next, these words stay.
Adaptive Biotechnologies Corporation · ADPT · Markup · $22.92
Recorded 2026-07-19 · before the outcome · scored mechanically
